Lung Cancer
Also known as: Bronchogenic carcinoma, Miliary, Seeded, Seeds, Small
Methodology & AI Transparency ⓘ
Lung Cancer Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is lung cancer? Lung cancer is cancer that forms in tissues of the lung, usually in the cells that line the air passages.
- 2 Real-world patient consensus: Diagnostic registry C34.90: Lung Cancer is managed within Cancer & Oncology (aka Bronchogenic carcinoma).
- 3 Typical cash cost range: Workup highlights for Lung Cancer (C34.90): targeted/immunotherapy [Lung Cancer C34.90].
- 4 Top reported side effects / signs: Key Cancer & Oncology biomarkers for Lung Cancer (C34.90): Comprehensive Metabolic & in Lung Cancer (C34.90: Organ Function Panel) & Pathology / Molecular in Lung Cancer (C34.90: Genomic Staging) (Guideline-concordant surveillance (C34.90)).
Ask our AI Specialists anything about Lung Cancer
What Is Lung Cancer?
What is lung cancer? Lung cancer is cancer that forms in tissues of the lung, usually in the cells that line the air passages. It is the leading cause of cancer death in both men and women. There are two main types: small cell lung cancer and non-small cell lung cancer . These two types grow differently and are treated differently. Non-small cell lung cancer is the more common type. Who is more likely to develop lung cancer? Anyone can develop lung cancer, but certain factors raise your risk of getting it: Smoking . This is the most important risk factor for lung cancer.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Lung Cancer (C34.90, Cancer & Oncology) reflects potential lymphatic or in Lung Cancer (C34.90: hematogenous dissemination if). Cross-referenced with NIH MeSH (Lung Neoplasms), longitudinal control is benchmarked via Comprehensive Metabolic & in Lung Cancer (C34.90: Organ Function Panel).
Common Symptoms & Clinical Signs
- • A family history of lung cancer
- • Being exposed to asbestos , arsenic , chromium, beryllium, nickel, soot, or tar in the workplace
- • Presentation of Lung Cancer (C34.90): persistent painless lump, in Lung Cancer (C34.90: non-healing ulcer/mole change,)
- • Secondary Lung Cancer clinical sign: unintended weight loss [Lung Cancer C34.90]
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Lung Cancer Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C34.90 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Lung Cancer (C34.90: Organ Function Panel) | Preserved renal/hepatic clearance (C34.90) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Lung Cancer (C34.90: Genomic Staging) | Guideline-concordant surveillance (C34.90) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Lung Cancer (C34.90: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C34.90) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Lung Cancer
Treatment selection for Lung Cancer depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Lung Cancer)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Metformin improves survival in lung cancer patients with type 2: What a 4,397-Participant Study Found Ten studies, involving 4397 participants, were included. Medicina clinica • 2019-04-18 • Meta-Analysis | N = 4,397 | 94/100 | PMID 30173870 ↗ |
| New Insights on Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients: What a 437-Participant Study Found Patients with LM had a dismal prognosis, anlotinib could lead to a better PFS in pretreated NSCLC patients, which suggested anlotinib is a potential third-line or further therapy in these patients. Journal of cancer research and clinical oncology • 2023-04-15 • Phase III Randomized Trial | N = 437 | 93/100 | PMID 35482076 ↗ |
| New Insights on Benefits and safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients: What a 357-Participant Study Found Denosumab biosimilar QL1206 had promising efficacy, tolerable safety, and how the body absorbs the medicine equivalent to denosumab and could benefit patients with bone metastases from solid tumors. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy • 2023-03-15 • Phase III Randomized Trial | N = 357 | 93/100 | PMID 36802320 ↗ |
| Can This Approach Help? Inside the Latest Research on Ensartinib in ALK-Positive Non–Small-Cell Lung New England Journal of Medicine, Volume 395, Issue 17 , Page 1767-1768, October 29, 2026. New England Journal of Medicine • 2026-10-28 • Peer-Reviewed Journal (Clinical Trials) | Multi-cohort | 92/100 | PMID NEJM-3241120264 ↗ |
| Can This Approach Help? Inside the Latest Research on Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line From the US payer perspective, the first-line treatment for ES-SCLC with pembrolizumab plus EP was not cost-effective compared with placebo plus EP. PloS one • 2021-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34780478 ↗ |
Lung Cancer Patient Community & “People Like Me” Threads
Filter Lung Cancer community threads and patient logs by age, biological sex, dosage, and treatment duration.